Coenzyme Q10: a lipid-soluble molecule of the respiratory chain

Coenzyme Q10 is one of the compounds that appear regularly in discussions of cellular energy metabolism and of ageing research. It is neither a vitamin nor a mineral, because the human body synthesises it itself, and it is found in every cell membrane. This article describes what the molecule is, where it comes from, in which forms it is sold and what research has examined.

Chemistry and structure

Coenzyme Q10 belongs to the group of ubiquinones. The molecule consists of a 1,4-benzoquinone ring carrying two methoxy groups and a methyl group, and of a long side chain built from isoprene units. The number of these units gives the compound its name: human ubiquinone carries ten of them, which is the Q10 in the designation. Other organisms carry side chains of different lengths; yeast, for example, mainly produces Q6, and rodents produce Q9.

The long isoprenoid chain makes the molecule strongly lipophilic. Coenzyme Q10 is therefore practically insoluble in water and is located within the lipid bilayers of cell membranes, above all in the inner mitochondrial membrane. The quinone ring can take up and release two electrons, which lets the molecule move between three oxidation states: the fully oxidised form ubiquinone, the one-electron intermediate semiquinone, and ubiquinol, the chemically reduced form that carries two hydroxyl groups instead of the two ring carbonyls.

Discovery

The compound was isolated in 1957 by Frederick Crane and colleagues at the University of Wisconsin from beef heart mitochondria. In the same period, the group around Karl Folkers at Merck determined its chemical structure and achieved its synthesis. The name ubiquinone refers to its ubiquitous occurrence: it has been detected in bacteria, plants, fungi and animals.

Role in the cell

In the inner mitochondrial membrane, coenzyme Q10 functions as a mobile electron carrier. It takes electrons from complex I and complex II of the respiratory chain, as well as from further flavin-dependent enzymes such as the electron-transferring flavoprotein of fatty acid oxidation, and passes them to complex III. This electron transport is coupled to the proton gradient from which the cell generates ATP. Outside the mitochondria, ubiquinol is described in the literature as a lipid-soluble redox partner in membranes, where it participates in the regeneration of tocopherol radicals. These are descriptions of biochemical function, not statements about outcomes in people.

Biosynthesis and occurrence in food

The body produces coenzyme Q10 in most tissues. The quinone ring is derived from tyrosine or from 4-hydroxybenzoate, while the isoprenoid side chain comes from the mevalonate pathway, the same pathway that also leads to cholesterol. Tissue concentrations differ considerably: measurements show the highest values in heart, kidney and liver, and lower values in lung and blood plasma. Analyses of human tissue samples describe a decline in concentration from roughly the third decade of life onwards; whether this decline has consequences for health is an open research question.

In food, coenzyme Q10 occurs in organ meat, muscle meat, oily fish such as sardines and mackerel, soy and rapeseed oil, nuts and some vegetables. Estimates of the average daily dietary intake in Western countries lie in the range of a few milligrams, far below the amounts used in clinical studies.

Statins and the mevalonate pathway

Statins inhibit the enzyme HMG-CoA reductase, an early step of the mevalonate pathway. Because the isoprenoid side chain of coenzyme Q10 is built in the same pathway, measurements of blood concentrations during statin therapy show falling coenzyme Q10 values. Whether this fall explains the muscle complaints that some patients report during statin therapy has been examined in a number of randomised trials with varying results, and reviews describe the evidence as inconsistent. Any question about statin therapy belongs with the prescribing physician.

Research findings

The following studies are reported as they appear in the literature. They refer to the populations and doses examined and cannot be generalised.

  • Chronic heart failure: a multicentre randomised trial published in 2014 (Q-SYMBIO) assigned 420 patients with chronic heart failure to 300 mg of coenzyme Q10 daily or placebo over two years and reported a difference between the groups in a combined cardiovascular endpoint. Commentators pointed to the modest number of participants and to the many study centres involved, and called for confirmation in larger trials.
  • Blood pressure: several meta-analyses of small trials have reported differences of a few millimetres of mercury in systolic values. A later Cochrane review that applied stricter inclusion criteria found the data insufficient to draw a conclusion.
  • Parkinson disease: the QE3 trial, published in 2014, randomised 600 participants with early Parkinson disease to 1200 mg or 2400 mg of coenzyme Q10 daily or placebo. The trial was stopped early for futility because no difference from placebo was observed in the rating scales used.
  • Migraine: a 2005 randomised trial in 42 adults used 300 mg daily over three months and reported a difference in attack frequency compared with placebo. Later reviews describe the body of evidence as small and heterogeneous.
  • Fertility parameters: small trials in men with impaired semen parameters have reported changes in sperm concentration and motility during intake of 200 to 300 mg daily. The participant numbers are low and the clinical meaning of the measured differences is not established.
  • Statin-associated muscle symptoms: randomised trials have compared coenzyme Q10 with placebo in patients reporting muscle complaints during statin therapy. Published results point in both directions, and systematic reviews describe the question as unresolved.

Forms on the market

  1. Ubiquinone: the oxidised form, chemically stable and the form used in most published trials. It is made industrially by fermentation with bacteria or yeasts, or by chemical synthesis.
  2. Ubiquinol: the reduced form, sensitive to oxygen and therefore sold in sealed soft capsules with added antioxidants. Comparative pharmacokinetic studies of the two forms have produced differing results.
  3. Solubilised preparations: because of the lipophilic character of the molecule, formulations with oils, emulsifiers, cyclodextrins or liposomes are used. Studies of these preparations measure plasma concentrations after intake; they do not examine clinical endpoints.

Pharmacokinetic studies consistently describe absorption as slow and limited, and higher plasma concentrations are measured when the substance is taken together with a fat-containing meal. Doses used in published trials range from 60 mg to 2400 mg per day; these are study doses and not a recommendation.

Safety data and interactions

Reported adverse effects are mostly mild gastrointestinal complaints such as nausea, upper abdominal discomfort or loose stools. The following points are documented and should be observed:

  • Because the quinone ring resembles vitamin K structurally, an interaction with vitamin K antagonists such as warfarin or phenprocoumon is discussed; case reports describe changes in INR values.
  • Interactions with medicines for diabetes and with antihypertensive medicines are described, since both blood glucose and blood pressure readings may be affected.
  • Data on use during pregnancy and breastfeeding are insufficient.
  • Anyone taking prescription medicines or living with a chronic condition should discuss the use of supplements with a physician beforehand.

Regulatory status in the European Union

Coenzyme Q10 is marketed in the EU as a food supplement. No health claim for coenzyme Q10 has been authorised under Regulation (EC) No 1924/2006; the applications submitted were assessed by EFSA and not authorised. Statements about physiological function in advertising are therefore not permitted in the EU.

Open questions

  • How much of an oral dose reaches mitochondria in tissue, rather than only the plasma compartment, is not well characterised in humans.
  • Whether the measured age-related decline in tissue concentration is a cause or a consequence of other changes is unresolved.
  • Comparative data on ubiquinone and ubiquinol are limited and partly contradictory.
  • Long-term data in healthy adults are scarce; most trials ran for weeks to months.